OriCiro Genomics is a cell-free genome technology company. The company offers the next-generation technology of large DNA synthesis and manufacturing for gene therapy and synthetic biology. One of company's core technologies enables cell-free, thereby efficient amplification of large DNA molecules aiming to replace conventional E. coli cloning. It can not only streamline current R&D and manufacturing processes but also widen significantly the scope of research and its applications for a wide range of purposes including pharmaceuticals and diagnostics. Company’s mission is to create a better Bioeconomy with innovate genome technologies. OriCiro was established in December 2018, located in Tokyo, as a spin-out from Rikkyo University and raised $3.6M in March 2019. The company has a strong portfolio of patent and applications. What the company offers includes reagent kits for cell-free DNA cloning for academia research, and technology licensing to corporate partners.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Cell-free DNA synthesis and manufacturing Technology
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):